A research team has discovered a previously unknown mechanism that could explain why many patients with aggressive B-cell lymphoma do not respond to CAR-T cell therapy in the long term. The results of ...
ctDNA testing could help doctors track response, reduce unnecessary chemo, and identify relapse early for patients with aggressive B cell lymphomas. Dr. Hua-Jay Cherng, a hematologist oncologist at ...
Combination of mitoxantrone hydrochloride liposome with tislelizumab in patients with relapsed or refractory NK/T cell lymphoma: A phase Ib/II study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results